Research programme: inflammatory bowel disease therapeutics - Renexxion
Latest Information Update: 12 Oct 2023
At a glance
- Originator Renexxion
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammatory bowel diseases